CLU and idiopathic pulmonary fibrosis: Future work should prioritize in vivo validation of these compounds in IPF models, large-scale multicenter cohorts to confirm biomarker utility, and mechanistic studies to resolve CLU/LCN2’s compartment-specific roles.